We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RACE:NYSEFerrari N.V. Analysis

Data as of 2026-03-16 - not real-time

$331.05

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Ferrari (RACE) trades around $331, just above its 20‑day SMA ($358) but well below the 200‑day SMA ($422), signaling a long‑term downtrend despite a neutral short‑term direction. The RSI of 34 suggests the stock is approaching oversold territory, while a bearish MACD histogram reinforces momentum weakness. Volatility is elevated at 40% over the past 30 days, yet the beta of 0.65 points to lower systematic risk relative to the market. Fundamentally, the company boasts a 51.7% gross margin, a 28.6% operating margin, and a solid ROE of 42.9%, supported by a healthy cash position and a modest payout ratio of 33%.
However, the DCF fair value of roughly $68 is dramatically lower than the current price, implying the stock is significantly overvalued. Strong order books and a strategic buy‑back program provide upside catalysts, but the valuation gap and high short‑term volatility suggest caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near recent support at $329.33
  • Bearish MACD and low RSI indicating potential short‑term bounce risk
  • Decreasing volume trend limiting immediate upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong profitability metrics (gross margin >50%, operating margin >28%)
  • Robust cash flow and low payout ratio supporting dividend sustainability
  • Positive analyst sentiment (median target $429) and strategic buy‑back program

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Premium brand positioning and limited production capacity ensuring pricing power
  • Exposure to consumer‑cyclical demand and macro‑economic cycles
  • Significant valuation premium relative to DCF fair value requiring re‑rating

Key Metrics & Analysis

Financial Health

Revenue Growth3.80%
Profit Margin22.35%
P/E Ratio32.0
ROE42.89%
ROA13.75%
Debt/Equity73.68
P/B Ratio13.1
Op. Cash Flow$2.3B
Free Cash Flow$839.1M

Technical Analysis

TrendNeutral
RSI34.0
Support$329.33
Resistance$381.76
MA 20$358.25
MA 50$355.14
MA 200$422.43
MACDBearish
VolumeDecreasing
Fear & Greed Index78.27

Valuation

Fair Value$67.63
Target Price$440.38
Upside/Downside33.03%
GradeOvervalued
TypeGrowth
Dividend Yield1.29%

Risk Assessment

Beta0.65
Volatility40.36%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.